Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Synthetic XNA as bio-tool to eliminate genetic diseases in humans

Reference number
Coordinator Moligo Technologies AB
Funding from Vinnova SEK 772 324
Project duration November 2024 - May 2025
Status Completed
Venture Emerging technology solutions
Call Moonshots through synthetic biology

Important results from the project

The project successfully met its initial goals, demonstrating the feasibility of using engineered polymerases with modified XNTPs. It also validated CSR as an effective selection method and yielded three promising polymerase variants. Beyond expectations, the project deepened understanding of how chemical modifications impact enzyme performance, laying the groundwork for future development of programmable XNA tools for treating genetic diseases.

Expected long term effects

The project is expected to have important long-term effects by enabling gene therapies using engineered XNA biomolecules. By overcoming key challenges in polymerase engineering for modified dNTPs, it lays the foundation for stable, programmable molecules that target genetic mutations precisely. Combined with improved delivery methods, this work could lead to safer, more effective, and potentially curative treatments for many genetic diseases, while advancing synthetic biology and diagnostics.

Approach and implementation

The project followed the original plan closely, with key activities—such as XNTP synthesis, polymerase testing, and CSR-based selection—executed as intended. The timeline was maintained, and the chosen approach proved suitable. While no new collaborations were formally established, the project sparked interest among our existing partners, particularly those active in non-viral gene therapy and in vivo gene editing. No external disruptions occurred, and the project delivered its intended results.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 4 July 2025

Reference number 2024-03817